Genetics of Hypertension Associated Treatments (GenHAT)
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Peripheral Vascular Disease, Peripheral Vascular Disease, Cardiology, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 4/17/2018 |
| Start Date: | September 1999 |
| End Date: | August 2005 |
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
To examine whether the association between selected hypertensive genes and combined fatal
coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is
modified by the type of antihypertensive treatment, leading to differential risks of coronary
heart disease.
coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is
modified by the type of antihypertensive treatment, leading to differential risks of coronary
heart disease.
BACKGROUND:
The study might shed important light on the variation in patient response to antihypertensive
agents, and improve the ability to pick the right antihypertensive for specific patients.
GenHAT is an ancillary study to ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial). ALLHAT recruited 42,515 hypertensives and randomized them to one
of four antihypertensive agents (lisinopril, chlorthalidone, amlodipine, and doxazosin);
follow-up will be completed in March, 2002.
DESIGN NARRATIVE:
GenHAT, a prospective study ancillary to ALLHAT, will characterize hypertension genetic
variants and determine their interaction with antihypertensive treatments in relation to
coronary heart disease (CHD). DNA from frozen clots stored at the ALLHAT Central Laboratory
will be used to genotype variants of hypertension genes (angiotensinogen -6, angiotensin
converting enzyme insertion/deletion, angiotensin type- 1 receptor, alpha-adducin, beta2
adrenergic receptor, lipoprotein lipase, and 10 new hypertension variants expected to be
discovered during the course of the study). In addition to the primary aim, a number of
secondary aims will be undertaken to evaluate gene- treatment interactions in relation to
other endpoints, including all-cause mortality, stroke, heart failure, left ventricular
hypertrophy, decreased renal function, peripheral arterial disease, and blood pressure
lowering. Because of the ethnic and gender diversity of ALLHAT, an assessment will be made of
the effects of these variants on outcomes in key subgroups (age >65 years, women, African
Americans, Type II diabetics), and whether the gene-treatment interactions in relation to
outcomes are consistent across subgroups.
The study might shed important light on the variation in patient response to antihypertensive
agents, and improve the ability to pick the right antihypertensive for specific patients.
GenHAT is an ancillary study to ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial). ALLHAT recruited 42,515 hypertensives and randomized them to one
of four antihypertensive agents (lisinopril, chlorthalidone, amlodipine, and doxazosin);
follow-up will be completed in March, 2002.
DESIGN NARRATIVE:
GenHAT, a prospective study ancillary to ALLHAT, will characterize hypertension genetic
variants and determine their interaction with antihypertensive treatments in relation to
coronary heart disease (CHD). DNA from frozen clots stored at the ALLHAT Central Laboratory
will be used to genotype variants of hypertension genes (angiotensinogen -6, angiotensin
converting enzyme insertion/deletion, angiotensin type- 1 receptor, alpha-adducin, beta2
adrenergic receptor, lipoprotein lipase, and 10 new hypertension variants expected to be
discovered during the course of the study). In addition to the primary aim, a number of
secondary aims will be undertaken to evaluate gene- treatment interactions in relation to
other endpoints, including all-cause mortality, stroke, heart failure, left ventricular
hypertrophy, decreased renal function, peripheral arterial disease, and blood pressure
lowering. Because of the ethnic and gender diversity of ALLHAT, an assessment will be made of
the effects of these variants on outcomes in key subgroups (age >65 years, women, African
Americans, Type II diabetics), and whether the gene-treatment interactions in relation to
outcomes are consistent across subgroups.
- not taking anti-hypertensive medication
- use of anti-hypertensives for less than two months with a baseline blood pressure
between 140/90 and 180/110
- use of anti-hypertensives for greater than two months with a blood pressure not
greater than 160/100
- at least one additional cardiovascular risk factor such as previous MI, stroke, type 2
diabetes, smoking, left ventricular hypertrophy or dyslipidemia
We found this trial at
1
site
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
